Uploaded June 2024 | Updated September 2026, 2 weeks ago
Pancreatic Cancer Vaccines With Amazing Results in Phase I
Pancreatic ductal adenocarcinoma is one of the most lethal cancers with a 5 year survival rate of less than 10%. mRNA designer/personalized vaccines are changing this situation. Let's review the results of phase I trials.
Want to get access to DrBeen at low price of $4.99/month? Click here: drbeen.com/med-nerd
Want to support this work?:
Buy me a coffee :-) buymeacoffee.com/DrMobeenSyed
Become my patron: patreon.com/mobeensyed?fan_landing=true
PayPal: paypal.me/mobeensyed?locale.x=en_US
My substack: mobeensyedmd.substack.com
#drbeen #koolbeens #HealthPolicy
Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.
URL list from Tuesday, Jun. 4 2024 11:37 AM
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches | Radiation Oncology | Full Text
ro-journal.biomedcentral.com/articles/10.1186/s13014-019-1345-6
NHS England Thousands of NHS patients to access trials of personalised cancer ‘vaccines’
england.nhs.uk/2024/05/thousands-of-nhs-patients-to-access-trials-of-personalised-cancer-vaccines
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer | BioNTech
investors.biontech.de/news-releases/news-release-details/three-year-phase-1-follow-data-mrna-based-individualized
Investigational mRNA Vaccine Induced Persistent Immune Response in Phase 1 Trial of Patients With Pancreatic Cancer | Memorial Sloan Kettering Cancer Center
mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out
Trial Design
biontech.com/int/en/home/pipeline-and-products/clinical-trials-new/trial-design.html
Cancer vaccines are having a renaissance | MIT Technology Review
technologyreview.com/2024/05/03/1092026/cancer-vaccines-are-having-a-renaissance
NHS England launches scheme to boost signups for personalised cancer vaccine trials | The BMJ
bmj.com/content/385/bmj.q1212#:~:text=The%20vaccines%20currently%20being%20trialled,identify%20and%20destroy%20cancer%20cells.
Pancreatic Cancer Vaccines With Amazing Results in Phase I
Pancreatic ductal adenocarcinoma is one of the most lethal cancers with a 5 year survival rate of less than 10%. mRNA designer/personalized vaccines are changing this situation. Let's review the results of phase I trials.
Want to get access to DrBeen at low price of $4.99/month? Click here: drbeen.com/med-nerd
Want to support this work?:
Buy me a coffee :-) buymeacoffee.com/DrMobeenSyed
Become my patron: patreon.com/mobeensyed?fan_landing=true
PayPal: paypal.me/mobeensyed?locale.x=en_US
My substack: mobeensyedmd.substack.com
#drbeen #koolbeens #HealthPolicy
Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.
URL list from Tuesday, Jun. 4 2024 11:37 AM
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches | Radiation Oncology | Full Text
ro-journal.biomedcentral.com/articles/10.1186/s13014-019-1345-6
NHS England Thousands of NHS patients to access trials of personalised cancer ‘vaccines’
england.nhs.uk/2024/05/thousands-of-nhs-patients-to-access-trials-of-personalised-cancer-vaccines
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer | BioNTech
investors.biontech.de/news-releases/news-release-details/three-year-phase-1-follow-data-mrna-based-individualized
Investigational mRNA Vaccine Induced Persistent Immune Response in Phase 1 Trial of Patients With Pancreatic Cancer | Memorial Sloan Kettering Cancer Center
mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out
Trial Design
biontech.com/int/en/home/pipeline-and-products/clinical-trials-new/trial-design.html
Cancer vaccines are having a renaissance | MIT Technology Review
technologyreview.com/2024/05/03/1092026/cancer-vaccines-are-having-a-renaissance
NHS England launches scheme to boost signups for personalised cancer vaccine trials | The BMJ
bmj.com/content/385/bmj.q1212#:~:text=The%20vaccines%20currently%20being%20trialled,identify%20and%20destroy%20cancer%20cells.
